263 related articles for article (PubMed ID: 9722289)
41. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
42. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
43. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With
Russell NH; Wilhelm-Benartzi C; Othman J; Dillon R; Knapper S; Batten LM; Canham J; Hinson EL; Betteridge S; Overgaard UM; Gilkes A; Potter N; Mehta P; Kottaridis P; Cavenagh J; Hemmaway C; Arnold C; Freeman SD; Dennis M;
J Clin Oncol; 2024 Apr; 42(10):1158-1168. PubMed ID: 38215358
[TBL] [Abstract][Full Text] [Related]
44. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
45. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
Montillo M; Mirto S; Petti MC; Latagliata R; Magrin S; Pinto A; Zagonel V; Mele G; Tedeschi A; Ferrara F
Am J Hematol; 1998 Jun; 58(2):105-9. PubMed ID: 9625576
[TBL] [Abstract][Full Text] [Related]
46. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation.
Ferrara F; Melillo L; Montillo M; Leoni F; Pinto A; Mele G; Mirto S
Ann Hematol; 1999 Aug; 78(8):380-4. PubMed ID: 10460353
[TBL] [Abstract][Full Text] [Related]
47. Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
Carella AM; Cascavilla N; Greco MM; Melillo L; Sajeva MR; Ladogana S; D'Arena G; Perla G; Carotenuto M
Leuk Lymphoma; 2001 Jan; 40(3-4):295-303. PubMed ID: 11426551
[TBL] [Abstract][Full Text] [Related]
48. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
49. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
50. Prospective, multicenter, phase II study on reducing the dosage of idarubicin and FLAG for patients younger than 65 years with resistant acute myeloid leukemia: a comparison with a higher dosage trial.
Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Park JH; Lee KH
Acta Haematol; 2014; 132(1):87-96. PubMed ID: 24513865
[TBL] [Abstract][Full Text] [Related]
51. FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report.
Visani G; Tosi P; Zinzani PL; Manfroi S; Zaccaria A; Testoni N; Lemoli RM; Rosti G; Pelliconi S; Tura S
Br J Haematol; 1994 Feb; 86(2):394-6. PubMed ID: 7515268
[TBL] [Abstract][Full Text] [Related]
52. Purine nucleoside analogues in the treatment of myleoid leukemias.
Robak T
Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
[TBL] [Abstract][Full Text] [Related]
53. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
Westhus J; Noppeney R; Dührsen U; Hanoun M
Leuk Lymphoma; 2019 Apr; 60(4):1014-1022. PubMed ID: 30277107
[TBL] [Abstract][Full Text] [Related]
54. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Fong CY; Grigoriadis G; Hocking J; Coutsouvelis J; Muirhead J; Campbell P; Paul E; Walker P; Avery S; Patil S; Spencer A; Schwarer A; Wei A
Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
[TBL] [Abstract][Full Text] [Related]
55. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
56. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
Jackson G; Taylor P; Smith GM; Marcus R; Smith A; Chu P; Littlewood TJ; Duncombe A; Hutchinson M; Mehta AB; Johnson SA; Carey P; MacKie MJ; Ganly PS; Turner GE; Deane M; Schey S; Brookes J; Tollerfield SM; Wilson MP
Br J Haematol; 2001 Jan; 112(1):127-37. PubMed ID: 11167793
[TBL] [Abstract][Full Text] [Related]
57. The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Lee SR; Yang DH; Ahn JS; Kim YK; Lee JJ; Choi YJ; Shin HJ; Chung JS; Cho YY; Chae YS; Kim JG; Sohn SK; Kim HJ
J Korean Med Sci; 2009 Jun; 24(3):498-503. PubMed ID: 19543516
[TBL] [Abstract][Full Text] [Related]
58. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Kell WJ; Burnett AK; Chopra R; Yin JA; Clark RE; Rohatiner A; Culligan D; Hunter A; Prentice AG; Milligan DW
Blood; 2003 Dec; 102(13):4277-83. PubMed ID: 12933575
[TBL] [Abstract][Full Text] [Related]
59. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
60. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia.
Huhmann IM; Watzke HH; Geissler K; Gisslinger H; Jäger U; Knöbl P; Pabinger I; Korninger L; Mannhalter C; Mitterbauer G; Schwarzinger I; Kalhs P; Haas OA; Lechner K
Ann Hematol; 1996 Dec; 73(6):265-71. PubMed ID: 9003155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
